CEO Anthony Davies on "Gottlieb's math"

January 18, 2023

Categories

By Dan Stanton, BioProcess International "With cell and gene therapies coming of age, experts at Advanced Therapies Week looked to reducing COGs, novel payer models, and even biosimilars to tackle their spiraling price tags... Read entire article here: https://bioprocessintl.com/bioprocess-insider/therapeutic-class/10-cgt-approvals-in-2022-brings-gottliebs-math-close-to-realization/

Sara Mills co-authors "Process evolution in C and GT from discovery to commercialization"

Anthony offers insights with Endpoints News

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

The next frontier of in vivo gene therapy: are LNPs the new AAV?

Stay Informed

Subscribe to our mailing list for the latest insights on advanced therapy development, regulatory updates, industry trends, and upcoming events from Dark Horse Consulting Group.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

We respect your privacy. Unsubscribe at any time. We will never sell your information.